biostudies-literatureKim WSNCI NIH HHS65-73https://www.ebi.ac.uk/biostudies/studies/S-EPMC11701429biostudies-literatureUnknown31(1)<h4>Purpose</h4>Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) generally have poor prognoses and limited treatment options. This study evaluated the efficacy of a novel CD30/CD16A bispecific innate cell engager, acimtamig (AFM13), in patients with R/R PTCL.<h4>Patients and methods</h4>Patients included those with CD30 expression in ≥1% of tumor cells and who were R/R following ≥1 prior line of systemic therapy. Acimtamig (200 mg) was administered once weekly in 8-week cycles. The primary endpoint was the overall response rate by fluorodeoxyglucose-PET per independent review committee; secondary and exploratory endpoints included duration of response, safety, progression-free survival, and overall survival.<h4>Results</h4>The overall response rate in 108 patienClinical cancer research : an official journal of the American Association for Cancer ResearchA Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas.PMC11701429P30 CA008748Alexis KPinto SHorwitz SOveresch AMikhailova NRadeski DDomingo Domenech EHajela PRavenstijn PPietzko KShortt JGarcia LElbadri RKim WSZinzani PLSawas AEmig MRibrag VfalseA Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas.<h4>Purpose</h4>Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) generally have poor prognoses and limited treatment options. This study evaluated the efficacy of a novel CD30/CD16A bispecific innate cell engager, acimtamig (AFM13), in patients with R/R PTCL.<h4>Patients and methods</h4>Patients included those with CD30 expression in ≥1% of tumor cells and who were R/R following ≥1 prior line of systemic therapy. Acimtamig (200 mg) was administered once weekly in 8-week cycles. The primary endpoint was the overall response rate by fluorodeoxyglucose-PET per independent review committee; secondary and exploratory endpoints included duration of response, safety, progression-free survival, and overall survival.<h4>Results</h4>The overall response rate in 108 patien2025-01-01T00:00:00Z2025 Jan2026-06-01T11:04:29.571Z2026-04-08T11:32:32.89ZS-EPMC117014293953153810.1158/1078-0432.CCR-24-1913